Serum paraoxonase activity in uremic predialysis and hemodialysis patients

Journal of Nephrology

Volumn 17, Issue 6, 2004, Pages 813-818

  Dirican, Melahat ^a   Akça, Ramazan ^a   Sarandöl, Emre ^a   Dilek, Kamil ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Hemodialysis; High density lipoprotein; Paraoxonase; Uremia

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLESTEROL; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; PHENYLACETIC ACID; TRIACYLGLYCEROL; UREA; URIC ACID; CARBOXYLESTERASE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LABORATORY TEST; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; PHENOTYPE; PROTEIN BLOOD LEVEL; UREA BLOOD LEVEL; UREMIA; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CREATININE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; UREA; UREMIA;

EID: 16644391990     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
2. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-4.
3. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-92.
4. Miller NE. Associations of high density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113: 589-97.
5. Parthasarathy S, Barnett J, Fong LG. High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim Biophys Acta 1990; 1044: 275-83.
6. Mackness MI, Abbott C, Durrington PN, Arrol S. The role of high-density lipoprotein in lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829-34.
7. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
8. Witzum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
9. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-35.
10. La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993; 87: 25-34.
11. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
12. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-80.
13. Aviram M. Does paraoxonase play role in susceptibility of cardiovascular disease? Mol Med Today 1999; 5: 381-6.
14. Hasselwander O, Savage DA, McMaster D, Loughrey CM, Mc-Namee PT, Middleton D, Nichols DP, Maxwell AP, Young IS. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999; 56: 289-98.
15. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005-8.
16. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
17. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-6.
18. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-3.
19. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-9.
20. Paragh G, Asztalos L, Seres I, Balogh Z, Locsey L, Karpati I, Matyus J, Katona E, Harangi M, Kakuk G. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999; 83: 126-31.
21. Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998; 44: 179-81.
22. Juretic D, Tadijanovic M, Rekic B, Simeon-Rudolf V, Reiner E, Baricic M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 2001; 42: 146-50.
23. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996; 247: 71-80.
24. Paragh G, Seres I, Balogh Z, Varga Z, Karpati I, Matyus J, Ujhelyi L, Kakuk G. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998; 80: 166-70.
25. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082-8.
26. Itahara T, Suehiro T, Ikeda Y, Inoue M, Nakamura T, Kumon Y, Kawada M, Hashimato K. Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb 2000; 7: 152-8.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin.Chem 1972; 18: 499-508.
28. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
29. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992; 30: 391-5.
30. Ak G, Ozgonul M, Sozmen EY, Aslan SL, Sozmen B. Renal cortical thickness and PON1 activity, both decrease in chronic renal failure. J Nephrol 2002; 15: 144-9.
31. Schiavon R, Battaglia P, De Fanti E, Fasolin A, Biasioli S, Targa L, Guidi G. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002; 324: 39-44.
32. Suehiro T, Ikeda Y, Shiinoki T, Inoue M, Kumon Y, Itahara T, Hashimoto K. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002; 9: 133-8.
33. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Oxidized phospholipids induce changes in hepatic paraoxonase and Apo but not monocyte chemoattractant protein-1 via interleukin-6. Biol Chem 2001; 276: 1923-9.
34. Biasioli JS, Schiavon R, Petrosino L, De Fanti E, Cavalcanti G, Battaglia P, Fasolin A. Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. ASAIO J 2003; 49: 295-9.
35. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997; 131: 229-36.
36. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired high density lipoprotein metabolism in uremic patients. Kidney Int 1992; 41: 1653-61.
37. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81: 766-79.
38. Borazan H, Ustun H, Yilmaz A. The effects of haemodialysis and peritoneal dialysis on serum lipoprotein (a) and C-reactive protein levels. J Int Med Res 2003; 31: 378-83.
39. Kimak E, Solski J. Serum lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Ren Fail 2002; 24: 187-95.
40. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58.
41. Kario K, Matsuo T, Kobayashi H, Matsuo M, Asada R, Koide M. High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost 1995; 74: 1020-4.
42. Stenvinkel P, Heimburger O, Tuck C, Berglund L. Apo(a) isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998; 53: 1336-42.